tbuckley/cabot-search huggingface dataset:
IL‐22 and IL‐22 binding protein (IL‐22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections
Authors: Mathieu Sertorio, Xunya Hou, Rodrigo F. Carmo, Hélia Dessein, Sandrine Cabantous, Mohammed Abdelwahed, Audrey Romano, Fernanda Albuquerque, Luydson Vasconcelos, Theomira Carmo, Jun Li, Arthur Varoquaux, Violaine Arnaud, Pablo Oliveira, Anas Hamdoun, Hongbin He, Suzan Adbelmaboud, Adil Mergani, Jie Zhou, Ahmed Monis, Leila Beltrao Pereira, Philippe Halfon, Marc Bourlière, Raymundo Parana, Mitermayer dos Reis, David Gonnelli, Patricia Moura, Nasr Eldin Elwali, Laurent Argiro, Yuesheng Li, Alain Dessein
Journal: Hepatology (2014)

Interleukin (IL)‐22 acts on epithelia, hepatocytes, and pancreatic cells and stimulates innate immunity, tissue protection, and repair. IL‐22 may also cause inflammation and abnormal cell proliferation. The binding of IL‐22 to its receptor is competed by IL‐22 binding protein (IL‐22BP), which may limit the deleterious effects of IL‐22. The role of IL‐22 and IL‐22BP in chronic liver diseases is unknown. We addressed this question in individuals chronically infected with schistosomes or hepatitis C virus (HCV). We first demonstrate that schistosome eggs stimulate production of IL‐22 transcripts and inhibit accumulation of IL22‐BP transcripts in schistosome‐infected mice, and that schistosome eggs selectively stimulate production of IL‐22 in cultures of blood leukocytes from individuals chronically infected with Schistosoma japonicum . High IL‐22 levels in cultures correlated with protection against hepatic fibrosis and portal hypertension. To test further the implication of IL‐22/IL‐22BP in hepatic disease, we analyzed common genetic variants of IL22RA2, which encodes IL‐22BP, and found that the genotypes, AA, GG of rs6570136 ( P = 0.003; odds ratio [OR] = 2), and CC, TT of rs2064501 ( P = 0.01; OR = 2), were associated with severe fibrosis in Chinese infected with S. japonicum . We confirmed this result in Sudanese (rs6570136 GG [ P = 0.0007; OR = 8.2], rs2064501 TT [ P = 0.02; OR = 3.1]), and Brazilians (rs6570136 GG [ P = 0.003; OR = 26], rs2064501 TC, TT ( P = 0.03; OR = 11]) infected with S. mansoni . The aggravating genotypes were associated with high IL22RA2 transcripts levels. Furthermore, these same variants were also associated with HCV‐induced fibrosis and cirrhosis (rs6570136 GG, GA [ P = 0.007; OR = 1.7], rs2064501 TT, TC ( P = 0.004; OR = 2.4]). Conclusions : These results provide strong evidence that IL‐22 protects against and IL‐22BP aggravates liver fibrosis and cirrhosis in humans with chronic liver infections. Thus, pharmacological modulation of IL‐22 BP may be an effective strategy to limit cirrhosis. (H epatology 2015;61:1321–1331)
Differential Effects of Vasopressin and Phenylalanine^2 Vasopressin on Regional Vascular Resistance and Renal Function.
Authors: E. Clinton Texter
Journal: Annals of Internal Medicine (1966)

s1 May 1966Differential Effects of Vasopressin and Phenylalanine2 Vasopressin on Regional Vascular Resistance and Renal Function.E. Clinton Texter Jr., M.D., F.A.C.P., Roncos Abella, M.D., Higino C. Laureta, M.D., Francesco del Greco, M.D., Ching-Chung Chou, M.D.E. Clinton Texter Jr., M.D., F.A.C.P., Roncos Abella, M.D., Higino C. Laureta, M.D., Francesco del Greco, M.D., Ching-Chung Chou, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-64-5-1153_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCertain synthetic analogues of vasopressin have been shown to have different pharmacologic effects. The effects related to the circulation may have clinical implications. In the present study the effect of octapressin (PLV-2) upon various regional vascular beds was compared to that of vasopressin. The experiments were performed in 42 dogs under pentobarbital anesthesia. Octapressin and vasopressin were administered at doses of 0.005 to 0.01 units/ml and 0.05 to 0.1 units/ml, respectively, by constant infusion into the superior mesenteric, left gastric, splenic, and renal arteries. Total resistance expressed in units of peripheral resistance was estimated for all vascular beds (J. Lab.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: E. Clinton TexterJr., M.D., F.A.C.P.; Roncos Abella, M.D.; Higino C. Laureta, M.D.; Francesco del Greco, M.D.; Ching-Chung Chou, M.D.Affiliations: Chicago, Illinois, and Oklahoma City, Oklahoma PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liverSystemic Vasoconstrictor and Renal Vasodilator Effects of PLV-2 (Octapressin) in Man 1 May 1966Volume 64, Issue 5Page: 1153-1153KeywordsAnesthesiaRenal arteriesVasopressin ePublished: 1 December 2008 Issue Published: 1 May 1966 PDF downloadLoading ...
Abstract 3511: Modulation of HIF-1α by topotecan is related to topoisomerase I-associated with HIF-1α mRNA in ovarian cancer
Authors: Basmina Parmakhtiar, Ernest Han, John P. Fruehauf
Journal: Cancer Research (2010)

Abstract Topotecan (TPT) is an agent which targets topoisomerase I (Topo I) and is used in the treatment of platinum-resistant and/or recurrent ovarian cancer. We have previously reported that topotecan inhibits hypoxia inducible factor 1α (HIF1α) stabilization, leading to decreased HIF-1α protein and depression of vascular endothelial growth factor (VEGF) levels in ovarian cancer cell lines. Furthermore, we have shown a Topo I: HIF-1α mRNA association using RNA-immunoprecipitation. The aim of this study was to further elucidate the mechanism by which topotecan knocks down HIF-1 alpha and the nature of its dependence on Topoisomerase I. CAOV3 (high Topo I expressing) ovarian cancer cells were used to carry out Topo I knockdown studies using Topo I siRNA in both normoxic and hypoxic (0.5% O2) conditions. Topo I and HIF-1α transcript levels were determined by quantitative PCR and protein expression was evaluated via western blot analysis. Topo I and HIF-1α protein levels were normalized to B-Actin controls. RT-PCR analysis did not show a significant decrease in HIF-1α transcript levels with Topo I siRNA treatment compared to untreated and negative control siRNA treated cells. An 80% decrease in Topo I protein expression was obtained using 30nM Topo I siRNA for both normoxic and hypoxic conditions. An ∼2.30 fold increase in HIF-1α protein expression was seen in Topo I knockdown cells compared to negative control siRNA treated cells after 800nM topotecan treatment under hypoxic conditions. 800nM TPT yielded an 80% decrease in Topo I protein expression with negative control siRNA treated cells under both normoxic and hypoxic conditions. However, 800nM TPT showed complete inhibition of Topo I protein stabilization in Topo I siRNA treated cells. Our results suggest that Topo I is required for Topotecan to inhibit HIF-1α protein stabilization. Furthermore, they also suggest that Topo I may be modulating its own transcript levels. Further studies are being carried out to verify these findings and will be reported at the AACR conference. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3511.
Virus-Encoded Serine Proteinase Inhibitor SERP-1 Inhibits Atherosclerotic Plaque Development After Balloon Angioplasty
Authors: Alexandra Lucas, Li-ying Liu, Joanne Macen, Piers Nash, Erbin Dai, Michael Stewart, Kathryn Graham, Wai Etches, Lynn Boshkov, Patric N. Nation, Dennis Humen, Marita Lundstrom Hobman, Grant McFadden
Journal: Circulation (1996)

Background Recurrent atherosclerotic plaque growth, restenosis, is a significant clinical problem after interventional procedures. Initiation of restenosis involves activation of inflammatory and thrombotic cascades, which are regulated by serine proteinase enzymes and inhibitors. We have investigated the use of a viral serine proteinase inhibitor, SERP-1, to reduce plaque development after primary balloon angioplasty. This is the first experimental report of the use of a viral anti-inflammatory protein for the prevention of atherosclerosis. Methods and Results Seventy-four cholesterol-fed rabbits were treated with either local or systemic infusions of SERP-1 protein (or control solutions) after balloon-mediated injury. Sites of SERP-1 infusion in rabbits had dramatically reduced plaque compared with control infusions at the 4-week follow-up. At low-dose infusions (30 to 300 pg), only the primary infusion site had a demonstrable decrease in plaque, whereas at higher-dose infusions (&gt;3000 pg), a generalized reduction in plaque development was detected. An associated decrease in mononuclear cell infiltration of the arterial wall was detected after SERP-1 infusion within the first 24 hours. Infusion of an active-site mutant of SERP-1 (P 1 -P 1 ′, ala-ala) lacking serine proteinase inhibitory activity failed to prevent plaque growth. Conclusions Purified SERP-1, a virus-encoded secreted glycoprotein, reduces plaque growth after primary balloon-mediated injury. Plaque development is decreased by inhibition of serine proteinase activity and is associated with a focal reduction in macrophage infiltration immediately after injury. Investigation of serine proteinase inhibitors may provide new insight into the regulation of arterial responses to injury.
Effect of Basic Fibroblast Growth Factor on Myocardial Angiogenesis in Dogs With Mature Collateral Vessels
Authors: Matie Shou, Venugopal Thirumurti, M.A.Sharmini Rajanayagam, Daisy F Lazarous, Everett Hodge, Jonathan A Stiber, Mary Pettiford, Elizabeth Elliott, Sanjay M Shah, Ellis F Unger
Journal: Journal of the American College of Cardiology (1997)
RETENTION OF OSTEOGENIC CD14–MONOCYTES WITHIN THE CORONARY CIRCULATION CORRELATES WITH CORONARY CALCIFICATION
Authors: Julia Collin, Mario Goessl, Yoshiki Matsuo, Andreas Flammer, Darrell Loeffler, Ryan Lennon, Sundeep Khosla, Robert Simari, Daniel Spoon, Lilach Lerman, Amir Lerman
Journal: Journal of the American College of Cardiology (2013)
Management of Lymphoma
Authors: Dwight K. OXLEY
Journal: JAMA (1982)

<h3>To the Editor.—</h3> The review by John G. Allison, MD, of the surgeon's approach to the patient with known or suspected lymphoma (1981; 246:2843) omits an important step that must be taken immediately after tissue is excised, ie, freezing a portion of the biopsy specimen for surface marker studies and functional lymphocyte evaluation. The results of these procedures are useful in the differential diagnosis of lymphoma and the classification of lymphomas for purposes of therapy and prognosis. For example, when studying a case in which it is difficult to distinguish between atypical hyperplasia and lymphoma, the finding of a polyclonal surface marker pattern is important evidence favoring the former. If the patient is to receive the best available care, the primary physician and surgeon should involve a pathologist as a clinical consultant in planning the biopsy strategy as well as in the histological evaluation of tissues excised by the surgeon.
LOWER PROGRAMMED PACING RATES REDUCES ATRIAL FIBRILLATION BURDEN IN PATIENTS ON DOFETILIDE
Authors: Anand M. Pillai, Vivek Yarlagadda, Chanakyaram Reddy, Arun Sridhar, Madhu Reddy, Raghuveer Dendi
Journal: Journal of the American College of Cardiology (2014)
Mechanism of β1-integrin-mediated hepatoma cell growth involves p27 and S-phase kinase-associated protein 2
Authors: Hao Zhang, Iwata Ozaki, Toshihiko Mizuta, Tohru Yoshimura, Sachiko Matsuhashi, Akitaka Hisatomi, Jutaro Tadano, Takahiro Sakai, Kyosuke Yamamoto
Journal: Hepatology (2003)

Although cooperative interactions between growth factors and integrins, cell surface receptors for extracellular matrices (ECM), have been reported, little is known about the interaction between hepatocyte growth factor (HGF) and integrin in hepatoma cells. We investigated the effects and mechanisms of integrin on the proliferation of hepatoma cells regulated by HGF. Human HepG2 hepatoma cells stably transfected with beta 1-integrin were treated with HGF and compared with parental and mock-transfected control cells. Cell proliferation and expression of cyclin-dependent kinase (Cdk) inhibitors and S-phase kinase-associated protein 2 (Skp2), were investigated. HGF dose-dependently suppressed the proliferation of parental and mock-transfected HepG2 cells. However, cells overexpressing beta 1-integrin exhibited increased proliferation in response to HGF. Although HGF increased p27 and decreased Skp2 expression in the parental and mock-transfected cells, the p27 and Skp2 levels in cells overexpressing beta 1-integrin were not altered by HGF. Interestingly, HepG2 cells overexpressing beta 1-integrin showed increased Skp2 expression. Furthermore, HGF did not reduce the proliferation of HepG2 cells transfected with antisense p27 or sense Skp2. Thus, HGF suppresses HepG2 cell proliferation by directly increasing p27 expression and indirectly decreasing Skp2 expression, and beta 1-integrin modulates the responsiveness of hepatoma cells to HGF via a p27-dependent manner by increasing Skp2. In conclusion, these results strongly suggest that integrin-mediated signals from the ECM can modulate growth factor-mediated signals in hepatoma cells, and may contribute to the growth of hepatocellular carcinomas.
The Relation of Ambulatory Blood Pressure and Pulse Rate to Retinopathy in Type 1 Diabetes Mellitus
Authors: Ronald Klein, Scot E. Moss, Alan R. Sinaiko, Bernard Zinman, Robert Gardiner, Samy Suissa, Sandra M. Donnelly, Michael S. Kramer, Paul Goodyer, Trudy Strand, Michael Mauer
Journal: Ophthalmology (2006)
Pneumococcal Vaccine Efficacy
Authors: MARIA ALOIZOU
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 September 1986Pneumococcal Vaccine EfficacyMARIA ALOIZOU, M.D., STEVEN LOMASKY, M.D., PHILIP D. LIEF, M.D.MARIA ALOIZOU, M.D.Search for more papers by this author, STEVEN LOMASKY, M.D.Search for more papers by this author, PHILIP D. LIEF, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-3-463_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: In the January issue, Bolan and colleagues (1) describe their analysis of the distribution of pneumococcal serotypes isolated from blood and cerebrospinal fluid of vaccinated and nonvaccinated patients. Although we agree that their data support the use of pneumococcal vaccine in select segments of the population, caution must be used, particularly with regard to meningitis prophylaxis. A reanalysis of the data presented in Table 1 using a fourfold chi-square table reveals a significant increase in the percentage of total cerebrospinal fluid isolates obtained from vaccinated as opposed to nonvaccinated patients: 24. 9% compared with 11.7% (chi-square =...Reference1. BOLANBROOMEFACKLAMPLIKAYTISFRASERSCHLECH GCRBDW. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med. 1986;104:1-6. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Montefiore Medical Center Bronx, NY 10467 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1986Volume 105, Issue 3Page: 463-464KeywordsBloodCerebrospinal fluidMeningitisProphylaxisVaccines Issue Published: 1 September 1986 PDF downloadLoading ...
Complications Associated With Double Balloon Enteroscopy at Nine US Centers
Authors: Lauren B. Gerson, Jeffrey Tokar, Michael Chiorean, Simon Lo, G. Anton Decker, David Cave, Doumit BouHaidar, Daniel Mishkin, Charles Dye, Oleh Haluszka, Jonathan A. Leighton, Alvin Zfass, Carol Semrad
Journal: Clinical Gastroenterology and Hepatology (2009)
Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty
Authors: Teruo Inoue, Yoshihiko Sakai, Shigenori Morooka, Terumi Hayashi, Kan Takayanagi, Yutaka Takabatake
Journal: Journal of the American College of Cardiology (1996)
Vaccination against smallpox---1806
Authors: J. H. Baron
Journal: BMJ (2000)

There was no difference between groups (22% v 21% patients reported good effect).Versus oral NSAIDs: Five trials in the systematic review compared topical with oral NSAIDs but they all had inadequate design and power. 28Versus paracetamol: We found no RCTs. HarmsIn the systematic review, local adverse effects occurred in 3% of participants in both groups and systemic adverse events in 1%. 28In the trial of copper-salicylate gel, more participants taking the drug reported adverse reactions than with placebo (83% v 52%), most commonly skin reactions, and more withdrew from the trial because of these reactions (17% v 2%). 29 CommentSample size bias hampers the interpretation of the available trials.Further, no high quality trials have compared topical with systemic administration of the same NSAID, and no trials have compared a topical NSAID with paracetamol.It is therefore not possible to judge the relative benefit of this route of administration.
Drivers with sleep apnoea
Authors: N J Legg
Journal: BMJ (1995)

EDITOR,—Ashley Woodcock and Patricia Stone pose the major moral dilemma of how to manage patients with sleep apnoea who hold licences to drive public service or heavy goods vehicles and are reluctant to declare their illness to the Driver and Vehicle Licensing Agency.1 They mention the temptation to blackmail such patients into treatment with threats of driving bans. The issue …
Commercialized non-Camellia tea: traditional function and molecular identification
Authors: Ping Long, Zhanhu Cui, Yingli Wang, Chunhong Zhang, Na Zhang, Minhui Li, Peigen Xiao
Journal: Acta Pharmaceutica Sinica B (2014)

Non-Camellia tea is a part of the colorful Chinese tea culture, and is also widely used as beverage and medicine in folk for disease prevention and treatment. In this study, 37 samples were collected, including 33 kinds of non-Camellia teas and 4 kinds of teas (Camellia). Traditional functions of non-Camellia teas were investigated. Furthermore, non-Camellia teas of original plants were characterized and identified by molecular methods. Four candidate regions (rbcL, matK, ITS2, psbA-trnH) were amplified by polymerase chain reaction. In addition, DNA barcodes were used for the first time to discriminate the commercial non-Camellia tea and their adulterants, and to evaluate their safety. This study showed that BLASTN and the relevant phylogenetic tree are efficient tools for identification of the commercial non-Camellia tea and their adulterants. However, some sequences from original plants have not been found and there is a limitation of sequence number of original plants in GenBank. Submitting more original plant sequences to the GenBank will be helpful for evaluating the safety of non-Camellia teas.
Organisational downsizing, sickness absence, and mortality: 10-town prospective cohort study
Authors: Jussi Vahtera, Mika Kivimäki, Jaana Pentti, Anne Linna, Marianna Virtanen, Pekka Virtanen, Jane E Ferrie
Journal: BMJ (2004)

<h3>Abstract</h3> <b>Objective</b> To examine whether downsizing, the reduction of personnel in organisations, is a predictor of increased sickness absence and mortality among employees. <b>Design</b> Prospective cohort study over 7.5 years of employees grouped into categories on the basis of reductions of personnel in their occupation and workplace: no downsizing (&lt; 8% reduction), minor downsizing (8-18%), and major downsizing (&gt; 18%). <b>Setting</b> Four towns in Finland. <b>Participants</b> 5909 male and 16 521 female municipal employees, aged 19-62 years, who kept their jobs. <b>Main outcome measures</b> Annual sickness absence rate based on employers9 records before and after downsizing by employment contract; all cause and cause specific mortality obtained from the national mortality register. <b>Results</b> Major downsizing was associated with an increase in sickness absence (P for trend &lt; 0.001) in permanent employees but not in temporary employees. The extent of downsizing was also associated with cardiovascular deaths (P for trend &lt; 0.01) but not with deaths from other causes. Cardiovascular mortality was 2.0 (95% confidence interval 1.0 to 3.9) times higher after major downsizing than after no downsizing. Splitting the follow up period into two halves showed a 5.1 (1.4 to 19.3) times increase in cardiovascular mortality for major downsizing during the first four years after downsizing. The corresponding hazard ratio was 1.4 (0.6 to 3.1) during the second half of follow up. <b>Conclusion</b> Organisational downsizing may increase sickness absence and the risk of death from cardiovascular disease in employees who keep their jobs.
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Authors: Paul A. Moore, Wenjun Zhang, G. Jonah Rainey, Steve Burke, Hua Li, Ling Huang, Sergey Gorlatov, Maria Concetta Veri, Sudeepta Aggarwal, Yinhua Yang, Kalpana Shah, Linda Jin, Sunan Zhang, Leilei He, Tengfei Zhang, Valentina Ciccarone, Scott Koenig, Ezio Bonvini, Syd Johnson
Journal: Blood (2011)
Alcohol and Risk for Ischemic Stroke in Men: The Role of Drinking Patterns and Usual Beverage
Authors: Kenneth J. Mukamal, Alberto Ascherio, Murray A. Mittleman, Katherine M. Conigrave, Carlos A. Camargo, Ichiro Kawachi, Meir J. Stampfer, Walter C. Willett, Eric B. Rimm
Journal: Annals of Internal Medicine (2005)

Background: The association of light to moderate alcohol consumption with risk for ischemic stroke remains controversial, as do the roles of beverage type and drinking pattern. Objective: To assess the association of drinking patterns and beverage type with risk for ischemic stroke among men. Design: Prospective cohort study. Setting: United States. Participants: 38 156 male health professionals who were free of known cardiovascular disease or cancer at baseline in 1986. Measurements: With a semi-quantitative food-frequency questionnaire, the authors individually ascertained consumption of regular and light beer, red and white wine, and liquor every 4 years. Alcohol consumption was categorized as light (0.1 to 9.9 g/d, or <1 drink daily), moderate (10.0 to 29.9 g/d, or 1 to 2 drinks daily), and heavier (≥30.0 g/d, or ≥3 drinks daily). Results: During a follow-up period of 14 years, 412 cases of incident ischemic stroke were documented. Compared with abstainers, light drinkers had a multivariate-adjusted relative risk of 0.99 (95% CI, 0.72 to 1.37), moderate drinkers had a multivariate-adjusted relative risk of 1.26 (CI, 0.90 to 1.76), and heavier drinkers had a multivariate-adjusted relative risk of 1.42 (CI, 0.97 to 2.09; P = 0.01 for trend). Consumption of 10.0 to 29.9 g of alcohol per day on 3 to 4 days per week appeared to be associated with the lowest risk (relative risk, 0.68 [CI, 0.44 to 1.05]). Red wine consumption was inversely associated with risk in a graded manner (P = 0.02 for trend), but other beverages were not. The apparently higher risk for ischemic stroke with heavier alcohol use appeared to be most pronounced for the embolic subtype. Limitations: This study had limited power to examine specific drinking patterns and heavy drinking and could not assess risk for hemorrhagic stroke. Conclusions: In this sample of male health professionals, light and moderate average alcohol use was generally not associated with an increased risk for ischemic stroke, although drinking pattern and beverage type modified this relation. Intake of more than 2 drinks per day may be associated with a higher risk for ischemic stroke.